Industry
Biotechnology
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
May 02, 2024 | 10:01 am
Portfolio Pulse from Benzinga Newsdesk
May 01, 2024 | 10:19 am
Portfolio Pulse from Benzinga Newsdesk
April 30, 2024 | 10:13 am
Portfolio Pulse from Benzinga Newsdesk
March 01, 2024 | 7:09 pm
Portfolio Pulse from Benzinga Newsdesk
February 29, 2024 | 2:10 pm
Portfolio Pulse from Benzinga Newsdesk
February 23, 2024 | 5:11 pm
Portfolio Pulse from Avi Kapoor
February 22, 2024 | 12:23 pm
Portfolio Pulse from Benzinga Newsdesk
February 22, 2024 | 11:44 am
Portfolio Pulse from Benzinga Newsdesk
February 16, 2024 | 4:13 pm
Portfolio Pulse from Avi Kapoor
February 15, 2024 | 6:20 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.